AbbVie Inc. (ABBV) Operating Margin
- Operating margin · 12 months: Value 26.20%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 26.20% | Operating income / revenue. Period ending 2026-06-30. $16.87B ÷ $64.39B × 100 ≈ 26.20% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 16.87B USD | Operating Income (Loss) |
| Revenue | 64.39B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 18.36B USD | Cost of Goods and Services Sold |
| Research and development | (m) | |
| Selling, general and administration | 14.67B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16.87B | $64.39B | $18.36B | (m) | $14.67B | 26.20% |
| 2026-03-31 | $15.33B | $62.82B | $18.42B | (m) | $14.29B | 24.41% |
| 2025-12-31 | $15.07B | $61.16B | $18.20B | (m) | $14.01B | 24.65% |
| 2025-09-30 | $9.04B | $59.64B | $18.05B | (m) | $13.97B | 15.16% |
| 2025-06-30 | $10.97B | $58.33B | $16.96B | (m) | $14.61B | 18.80% |
| 2025-03-31 | $10.07B | $57.37B | $16.81B | (m) | $14.73B | 17.56% |
| 2024-12-31 | $9.14B | $56.33B | $16.90B | (m) | $14.75B | 16.22% |
| 2024-09-30 | $13.82B | $55.53B | $18.21B | (m) | $14.09B | 24.89% |
| 2024-06-30 | $12.27B | $55.00B | $20.48B | (m) | $13.26B | 22.31% |
| 2024-03-31 | $12.79B | $54.40B | $20.52B | (m) | $13.15B | 23.50% |
| 2023-12-31 | $12.76B | $54.32B | $20.41B | (m) | $12.87B | 23.49% |
| 2023-09-30 | $15.06B | $55.14B | $18.88B | (m) | $13.10B | 27.32% |
| 2023-06-30 | $17.39B | $56.02B | $17.42B | (m) | $13.03B | 31.03% |
| 2023-03-31 | $16.17B | $56.74B | $17.35B | (m) | $15.17B | 28.49% |
| 2022-12-31 | $18.12B | $58.05B | $17.41B | (m) | $15.26B | 31.21% |
| 2022-09-30 | $17.69B | $57.82B | $17.56B | (m) | $15.10B | 30.59% |
| 2022-06-30 | $17.39B | $57.35B | $16.93B | (m) | $14.88B | 30.33% |
| 2022-03-31 | $18.54B | $56.73B | $17.29B | (m) | $12.63B | 32.68% |
| 2021-12-31 | $17.92B | $56.20B | $17.45B | (m) | $12.35B | 31.89% |
| 2021-09-30 | $16.60B | $55.17B | $17.81B | (m) | $12.32B | 30.09% |
| 2021-06-30 | $15.55B | $53.73B | $18.47B | (m) | $12.08B | 28.95% |
| 2021-03-31 | $11.86B | $50.20B | $17.66B | (m) | $12.45B | 23.63% |
| 2020-12-31 | $11.36B | $45.80B | $15.39B | (m) | $11.30B | 24.81% |
| 2020-09-30 | $11.57B | $40.65B | $12.71B | (m) | $10.02B | 28.45% |
| 2020-06-30 | $10.93B | $36.23B | $9.58B | (m) | $8.83B | 30.17% |
| 2020-03-31 | $13.58B | $34.06B | $7.69B | (m) | $6.96B | 39.86% |
| 2019-12-31 | $12.98B | $33.27B | $7.44B | (m) | $6.94B | 39.03% |
| 2019-09-30 | $6.59B | $32.87B | $7.46B | (m) | $6.92B | 20.04% |
| 2019-06-30 | $7.13B | $32.62B | $7.37B | (m) | $7.18B | 21.85% |
| 2019-03-31 | $6.49B | $32.65B | $7.49B | (m) | $7.29B | 19.88% |
| 2018-12-31 | $6.38B | $32.75B | $7.72B | (m) | $7.40B | 19.49% |
| 2018-09-30 | $10.65B | $32.19B | (m) | (m) | $7.41B | 33.10% |
| 2018-06-30 | $10.19B | $30.95B | (m) | (m) | $6.94B | 32.92% |
| 2018-03-31 | $10.09B | $29.61B | (m) | (m) | $6.69B | 34.07% |
| 2017-12-31 | $9.59B | $28.22B | (m) | (m) | $6.28B | 33.99% |
| 2017-09-30 | $10.16B | $27.27B | (m) | (m) | $5.98B | 37.24% |
| 2017-06-30 | $9.81B | $26.71B | (m) | (m) | $5.91B | 36.74% |
| 2017-03-31 | $9.53B | $26.22B | (m) | (m) | $5.87B | 36.33% |
| 2016-12-31 | $9.38B | $25.64B | (m) | (m) | $5.86B | 36.60% |
| 2016-09-30 | $9.14B | $25.24B | (m) | (m) | $5.94B | 36.21% |
| 2016-06-30 | $8.66B | $24.75B | (m) | (m) | $6.03B | 35.00% |
| 2016-03-31 | $8.13B | $23.78B | (m) | (m) | $6.27B | 34.18% |
| 2015-12-31 | $7.54B | $22.86B | (m) | (m) | $6.39B | 32.97% |
| 2015-09-30 | $5.01B | $21.91B | (m) | (m) | $7.99B | 22.86% |
| 2015-06-30 | $4.08B | $20.99B | (m) | (m) | $8.11B | 19.46% |
| 2015-03-31 | $3.75B | $20.44B | (m) | (m) | $7.86B | 18.33% |
| 2014-12-31 | $3.41B | $19.96B | (m) | (m) | $7.72B | 17.09% |
| 2014-09-30 | $5.36B | $19.62B | (m) | (m) | $5.83B | 27.33% |
| 2014-06-30 | $5.77B | $19.26B | (m) | (m) | $5.50B | 29.97% |
| 2014-03-31 | $5.71B | $19.02B | (m) | (m) | $5.46B | 30.01% |
| 2013-12-31 | $5.66B | $18.79B | (m) | (m) | $5.35B | 30.14% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $5.82B | $18.38B | (m) | (m) | $4.99B | 31.65% |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $3.62B | $17.44B | (m) | (m) | $5.89B | 20.75% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |